Европейская академия естественных наук Hannover E.V.

Gu Yuchun

Gu Yuchun, Professor, as well as the founder, Chairman, and Chief Scientist of Allife Medicine, holds a distinguished PhD from the University of Birmingham. He has expanded his expertise through post-doctoral research at Imperial College London, subsequently acting as a researcher at the esteemed University of Cambridge. His leadership in the field of cardiovascular disease and stem cell therapy solidifies his position as a renowned authority in the scientific community.

During his tenure in the United Kingdom, Professor Gu Yuchun pioneered membrane electric clamp technology and calcifluorescence technology for cardiovascular diseases, establishing them as world-leading innovations with no peers. Simultaneously, he led and actively participated in multiple FP7 research projects conducted in the United Kingdom and the European Union. In 2011, Professor Gu Yuchun received a special invitation from Peking University and returned to China. Subsequently, he assumed the roles of Director, Professor, and Doctoral Supervisor at the Molecular Pharmacology Laboratory of the Institute of Molecular Medicine at Peking University. He contributed significantly to numerous projects, including National Program on Key Basic Research Project (973 Program), National Nature Major Projects, and National Natural Projects.

Gu Yuchun possesses world-leading independent research and development technology in the field of iPSC stem cells. He has led a team to optimize international-leading and efficient iPSC reprogramming technology. He achieved the milestone of China's first iPSC source cell drugs entering clinical trials, along with CAR-NK drugs. Additionally, he led the world's first iPSC source iEPC injection for the treatment of acute ischemic stroke, maintaining a continuous leadership position. Currently, Allife holds more than 100 independent research and development intellectual property rights and over 100 international and domestic technological invention patents in related fields. The NK cell-related patent pool, in particular, was awarded the second prize of the "2023 Invention and Innovation Award" by the China Association of Invention.

 

вверх

Энциклопедия ЕАЕН

 ¦  Impressum  ¦  Контакт